Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Lu AF11167 in Schizophrenia
NCT02202213Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Oct 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing Lu AF11167 with Placebo (2 arms). Primary endpoint: Absolute values and changes from baseline in safety variables. Started Oct 2013; status: completed.
02
Drugs
Lu AF11167
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02202213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202213.